Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine qualifies for phase II/III testing

July 16, 2018

Matinas collaborates with NINDS to develop HIV therapy based on LNC platform

July 10, 2018

Positive topline data presented from phase IIa study of ABX-464

July 4, 2018

Merck & Co. presents HIV integrase inhibitors

June 26, 2018

Biktarvy approved in Europe for the treatment of HIV-1 infection

June 26, 2018

Researchers present primary efficacy data on PRO-140 from CD02 study

June 22, 2018

Apabetalone reverses HIV-1 latency and induces apoptosis of reservoir cells

June 12, 2018

HIV-1 fusion peptide targeting, a promising vaccination strategy eliciting neutralizing antibodies

June 12, 2018

European Commission approves Juluca for HIV-1

May 22, 2018

Idenix Pharmaceuticals and Merck identify HIV-1 inhibitors

May 17, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...